

New Vice President at Vitrolife

Maria Forss has today been appointed Vice President, responsible for Business Development and Global Marketing. Maria Forss joins Vitrolife from P.U.L.S, where she is responsible for Business Development.

Maria has previously worked as the CEO of DuoCort Pharma, and at AstraZeneca in different positions within Marketing and Product Management. Maria takes up her post on October 1.

The role of Vice President is new and will strengthen Vitrolife's management function.

"With her solid experience of business development and marketing, Maria will be an excellent asset for us in the work of further strengthening Vitrolife's competitiveness. We warmly welcome Maria to the assignment of Vice President and I am pleased to gain yet another competent co-worker at Vitrolife," says Vitrolife's CEO Thomas Axelsson.

July 10, 2012
Gothenburg, Sweden
VITROLIFE AB (publ)
Thomas Axelsson
CEO

For further information, please contact:

Thomas Axelsson, CEO, +46 31 721 80 01

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 10, 2012 at 3:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.